<!DOCTYPE html>
<html>
<head>
<title>Epinephrine Auto-Injector Functional Test Training Manual</title>
<style>
  body { font-family: sans-serif; }
  .lang-toggle { position: fixed; top: 10px; right: 10px; }
  .en, .zh { display: none; }
  .active { display: block; }
</style>
</head>
<body>

<div class="lang-toggle">
  <button onclick="toggleLang('en')">English</button>
  <button onclick="toggleLang('zh')">中文</button>
</div>

<div id="en" class="en active">
<h1>Epinephrine Auto-Injector Functional Test Training Manual</h1>

<h2>Introduction</h2>

<p>This manual provides detailed procedures for conducting the five key functional tests for the Summed Medtech epinephrine auto-injector. These tests are designed to ensure the device's safety, efficacy, and compliance with regulatory standards, including the 2023 FDA draft guidance.</p>

<hr>

<h2>1. Dose Accuracy and Delivered Volume</h2>

<h3>1.1. Objective</h3>

<p>To verify that the auto-injector delivers the correct dose of epinephrine with a high degree of accuracy and precision. This test is critical for patient safety and is a key requirement from the FDA.</p>

<h3>1.2. Referenced Standards</h3>

<ul>
  <li><strong>ISO 11608-1:</strong> Needle-based injection systems for medical use — Requirements and test methods — Part 1: Needle-based injection systems.</li>
  <li><strong>FDA Guidance:</strong> Draft Guidance on Epinephrine (referencing population bioequivalence).</li>
</ul>

<h3>1.3. Equipment</h3>

<ul>
  <li>High-precision analytical balance (readability to 0.01 mg).</li>
  <li>Beakers or other suitable containers for collecting the dose.</li>
  <li>Temperature and humidity controlled test environment.</li>
</ul>

<h3>1.4. Sample Size and Method</h3>

<ul>
  <li><strong>Sample Size:</strong> A minimum of 30 devices from each of three different manufacturing batches should be tested.</li>
  <li><strong>Method:</strong> Samples should be randomly selected from each batch.</li>
</ul>

<h3>1.5. Procedure</h3>

<ol>
  <li>Acclimatize the devices to the controlled test environment for at least 4 hours.</li>
  <li>Record the weight of an empty, dry collection container.</li>
  <li>Activate the auto-injector, dispensing the full dose into the pre-weighed container.</li>
  <li>Record the weight of the container with the delivered drug.</li>
  <li>Calculate the net weight of the delivered drug.</li>
  <li>Convert the net weight to volume using the known density of the epinephrine solution.</li>
  <li>Repeat for all test samples.</li>
</ol>

<h3>1.6. Acceptance Criteria</h3>

<ul>
  <li>The delivered volume of each device must be within ±10% of the label claim (e.g., 0.3 mL ± 0.03 mL).</li>
  <li>The mean delivered volume for each batch should be within ±5% of the label claim.</li>
  <li>The results must meet the criteria for population bioequivalence (PBE) when compared to a reference listed drug (RLD).</li>
</ul>

<h3>1.7. Justification and Collaboration</h3>

<ul>
  <li><strong>Justification:</strong> This test directly addresses a critical safety parameter. An incorrect dose could lead to treatment failure or adverse events. It is a direct requirement from the FDA.</li>
  <li><strong>Collaboration:</strong>
    <ul>
      <li><strong>Summed Medtech:</strong> Responsible for the overall device design and performance, ensuring the delivery mechanism is consistent.</li>
      <li><strong>Stevanato (PFS Supplier):</strong> Must provide syringes with consistent dimensions and silicone lubrication to ensure smooth plunger movement and complete delivery.</li>
      <li><strong>Pharma Customer A:</strong> Must ensure the filling process is accurate and precise. The filling volume error directly impacts the delivered dose. Close collaboration on the acceptable range of filling volumes is essential.</li>
    </ul>
  </li>
</ul>

<hr>

<h2>2. Activation Force and User Handling</h2>

<h3>2.1. Objective</h3>

<p>To ensure the auto-injector is easy to use and can be activated by the target patient population, including those with limited hand strength.</p>

<h3>2.2. Referenced Standards</h3>

<ul>
  <li><strong>ISO 11608-1:</strong> Needle-based injection systems for medical use — Requirements and test methods — Part 1: Needle-based injection systems.</li>
  <li><strong>FDA Guidance:</strong> Human Factors Studies and Related Clinical Study Considerations in Combination Product Design and Development.</li>
</ul>

<h3>2.3. Equipment</h3>

<ul>
  <li>Force gauge with appropriate fixtures.</li>
  <li>Simulated injection pads.</li>
  <li>Video recording equipment.</li>
</ul>

<h3>2.4. Sample Size and Method</h3>

<ul>
  <li><strong>Activation Force:</strong> 30 devices per batch.</li>
  <li><strong>Human Factors Study:</strong> A diverse group of at least 15 participants per user group, representative of the target population.</li>
</ul>

<h3>2.5. Procedure</h3>

<ol>
  <li><strong>Activation Force:</strong>
    <ol>
      <li>Mount the device in the force gauge fixture.</li>
      <li>Measure the force required to remove the safety cap.</li>
      <li>Measure the peak force required to activate the device against the injection pad.</li>
    </ol>
  </li>
  <li><strong>User Handling:</strong>
    <ol>
      <li>Provide participants with the device and instructions for use.</li>
      <li>Observe them as they perform a simulated injection.</li>
      <li>Record any use errors, difficulties, or close calls.</li>
      <li>Conduct post-use interviews to gather feedback.</li>
    </ol>
  </li>
</ol>

<h3>2.6. Acceptance Criteria</h3>

<ul>
  <li><strong>Activation Force:</strong> The force to remove the cap and activate the device must be within the specified range (e.g., 2-5 N for cap removal, 15-30 N for activation).</li>
  <li><strong>User Handling:</strong> The study must demonstrate that users can operate the device safely and effectively with a high success rate (e.g., >95%).</li>
</ul>

<h3>2.7. Justification and Collaboration</h3>

<ul>
  <li><strong>Justification:</strong> This test is essential for ensuring that patients can use the device correctly in a high-stress emergency situation.</li>
  <li><strong>Collaboration:</strong>
    <ul>
      <li><strong>Summed Medtech:</strong> The design of the device, including the ergonomics of the body and the activation mechanism, is critical.</li>
      <li><strong>Stevanato:</strong> The properties of the syringe, such as the plunger's breakaway and gliding forces, can influence the overall activation force.</li>
    </ul>
  </li>
</ul>

<hr>

<h2>3. Injection Time and Needle Exposure</h2>

<h3>3.1. Objective</h3>

<p>To verify that the injection is completed within an appropriate time frame and that the needle is exposed for the correct duration to ensure proper drug delivery.</p>

<h3>3.2. Referenced Standards</h3>

<ul>
  <li><strong>ISO 11608-1:</strong> Needle-based injection systems for medical use — Requirements and test methods — Part 1: Needle-based injection systems.</li>
</ul>

<h3>3.3. Equipment</h3>

<ul>
  <li>High-speed camera (e.g., >1000 frames per second).</li>
  <li>Foam blocks with density similar to human tissue.</li>
  <li>Measurement software for analyzing video footage.</li>
</ul>

<h3>3.4. Sample Size and Method</h3>

<ul>
  <li>30 devices per batch.</li>
</ul>

<h3>3.5. Procedure</h3>

<ol>
  <li>Set up the high-speed camera to record the device's activation against a foam block.</li>
  <li>Activate the device.</li>
  <li>Analyze the video to determine:
    <ul>
      <li>The time from needle movement starting to the end of drug delivery.</li>
      <li>The maximum depth of needle penetration into the foam block.</li>
      <li>The total time the needle is exposed outside of the device housing.</li>
    </ul>
  </li>
</ol>

<h3>3.6. Acceptance Criteria</h3>

<ul>
  <li><strong>Injection Time:</strong> Within the specified range (e.g., 3-10 seconds).</li>
  <li><strong>Needle Penetration Depth:</strong> Within the range for intramuscular injection (e.g., 15-25 mm).</li>
  <li><strong>Needle Exposure:</strong> The needle should be shielded immediately after injection.</li>
</ul>

<h3>3.7. Justification and Collaboration</h3>

<ul>
  <li><strong>Justification:</strong> Correct injection time and depth are crucial for the pharmacokinetic profile of the drug. Needle safety is a primary safety concern.</li>
  <li><strong>Collaboration:</strong>
    <ul>
      <li><strong>Summed Medtech:</strong> The spring force and mechanism design determine the injection speed and needle dynamics.</li>
      <li><strong>Stevanato:</strong> The needle length and quality are critical for achieving the correct penetration depth.</li>
    </ul>
  </li>
</ul>

<hr>

<h2>4. Device Durability and Robustness</h2>

<h3>4.1. Objective</h3>

<p>To ensure the auto-injector can withstand the physical stresses of transportation and handling without compromising its functionality or safety.</p>

<h3>4.2. Referenced Standards</h3>

<ul>
  <li><strong>ASTM D4169:</strong> Standard Practice for Performance Testing of Shipping Containers and Systems.</li>
  <li><strong>ISO 11608-1:</strong> Needle-based injection systems for medical use — Requirements and test methods — Part 1: Needle-based injection systems.</li>
</ul>

<h3>4.3. Equipment</h3>

<ul>
  <li>Drop test apparatus.</li>
  <li>Vibration table.</li>
  <li>Environmental chambers (for temperature and humidity control).</li>
</ul>

<h3>4.4. Sample Size and Method</h3>

<ul>
  <li>A set of devices from one batch will be subjected to each stress condition. A separate set of devices should be used for each test.</li>
</ul>

<h3>4.5. Procedure</h3>

<ol>
  <li>Subject the devices to a sequence of tests as defined in a protocol based on ASTM D4169, including:
    <ul>
      <li><strong>Drop Test:</strong> Dropping the device from a specified height (e.g., 1 meter) onto a hard surface at various orientations.</li>
      <li><strong>Vibration Test:</strong> Simulating the vibrations that may occur during transport.</li>
      <li><strong>Environmental Test:</strong> Exposing the device to cycles of high and low temperatures and humidity.</li>
    </ul>
  </li>
  <li>After each stress test, visually inspect the devices for any damage.</li>
  <li>Perform all other functional tests (Dose Accuracy, Activation Force, etc.) on the stressed devices.</li>
</ol>

<h3>4.6. Acceptance Criteria</h3>

<ul>
  <li>No critical failures (e.g., cracks, activation) should occur during stress testing.</li>
  <li>The performance of the stressed devices in the functional tests should not deviate significantly from the unstressed control devices.</li>
</ul>

<h3>4.7. Justification and Collaboration</h3>

<ul>
  <li><strong>Justification:</strong> Patients carry these devices with them, so they must be robust enough to function reliably when needed.</li>
  <li><strong>Collaboration:</strong>
    <ul>
      <li><strong>Summed Medtech:</strong> Responsible for the material selection and structural design of the device housing and components.</li>
      <li><strong>Stevanato:</strong> The glass syringe must be robust enough to withstand the stresses without breaking or cracking.</li>
    </ul>
  </li>
</ul>

<hr>

<h2>5. Container Closure Integrity (CCI)</h2>

<h3>5.1. Objective</h3>

<p>To ensure the sterility of the drug product by verifying that the container closure system (the syringe and its components) prevents microbial contamination.</p>

<h3>5.2. Referenced Standards</h3>

<ul>
  <li><strong>USP &lt;1207&gt;:</strong> Package Integrity Evaluation—Sterile Products.</li>
  <li><strong>ISO 11608-3:</strong> Needle-based injection systems for medical use — Requirements and test methods — Part 3: Finished containers.</li>
</ul>

<h3>5.3. Equipment</h3>

<ul>
  <li>Helium mass spectrometer leak detector or dye bath with vacuum chamber.</li>
</ul>

<h3>5.4. Sample Size and Method</h3>

<ul>
  <li>A statistically significant number of devices from each batch, tested at the beginning and end of the product's shelf life.</li>
</ul>

<h3>5.5. Procedure (Helium Leak Method)</h3>

<ol>
  <li>Place the device in a chamber filled with helium under pressure for a set period.</li>
  <li>Remove the device and place it in a vacuum chamber connected to a mass spectrometer.</li>
  <li>Measure the rate of helium leaking out of the device.</li>
</ol>

<h3>5.6. Acceptance Criteria</h3>

<ul>
  <li>The leak rate must be below the maximum allowable limit, which is correlated with preventing microbial ingress (e.g., &lt;10^-6 std-cc/sec).</li>
</ul>

<h3>5.7. Justification and Collaboration</h3>

<ul>
  <li><strong>Justification:</strong> A breach in CCI can lead to contamination of the sterile drug product, posing a serious risk to patient safety.</li>
  <li><strong>Collaboration:</strong>
    <ul>
      <li><strong>Summed Medtech:</strong> The design of the auto-injector must not compromise the integrity of the PFS. The assembly process is critical.</li>
      <li><strong>Stevanato:</strong> Must provide a high-quality PFS with a proven CCI. The selection of the plunger and tip cap materials is critical.</li>
      <li><strong>Pharma Customer A:</strong> The filling and finishing process must not damage the syringe or compromise its integrity.</li>
    </ul>
  </li>
</ul>

</div>

<div id="zh" class="zh">
<h1>肾上腺素自动注射器功能测试培训手册</h1>

<h2>介绍</h2>

<p>本手册提供了为Summed Medtech肾上腺素自动注射器进行五项关键功能测试的详细程序。这些测试旨在确保设备的安全、有效，并符合包括2023年FDA指南草案在内的法规标准。</p>

<hr>

<h2>1. 剂量准确度和输送体积</h2>

<h3>1.1. 目的</h3>

<p>验证自动注射器能够以高度的准确性和精密度输送正确剂量的肾上腺素。该测试对患者安全至关重要，是FDA的一项关键要求。</p>

<h3>1.2. 参考标准</h3>

<ul>
  <li><strong>ISO 11608-1:</strong> 医疗用针式注射系统 - 要求和测试方法 - 第1部分：针式注射系统。</li>
  <li><strong>FDA指南:</strong> 肾上腺素指南草案（参考群体生物等效性）。</li>
</ul>

<h3>1.3. 设备</h3>

<ul>
  <li>高精度分析天平（可读性至0.01毫克）。</li>
  <li>用于收集剂量的烧杯或其他合适的容器。</li>
  <li>温湿度受控的测试环境。</li>
</ul>

<h3>1.4. 样本量和方法</h3>

<ul>
  <li><strong>样本量:</strong> 应从三个不同生产批次中，每批至少测试30个设备。</li>
  <li><strong>方法:</strong> 样本应从每批中随机抽取。</li>
</ul>

<h3>1.5. 程序</h3>

<ol>
  <li>将设备在受控测试环境中适应至少4小时。</li>
  <li>记录一个空的、干燥的收集容器的重量。</li>
  <li>激活自动注射器，将全部剂量分配到预先称重的容器中。</li>
  <li>记录装有输送药物的容器的重量。</li>
  <li>计算输送药物的净重。</li>
  <li>使用肾上腺素溶液的已知密度将净重转换为体积。</li>
  <li>对所有测试样本重复此过程。</li>
</ol>

<h3>1.6. 验收标准</h3>

<ul>
  <li>每个设备的输送体积必须在标签声称的±10%以内（例如，0.3毫升±0.03毫升）。</li>
  <li>每批的平均输送体积应在标签声称的±5%以内。</li>
  <li>与参比药品（RLD）相比，结果必须符合群体生物等效性（PBE）的标准。</li>
</ul>

<h3>1.7. 理由与合作</h3>

<ul>
  <li><strong>理由:</strong> 该测试直接解决了一个关键的安全参数。不正确的剂量可能导致治疗失败或不良事件。这是FDA的直接要求。</li>
  <li><strong>合作:</strong>
    <ul>
      <li><strong>Summed Medtech:</strong> 负责整体设备设计和性能，确保输送机制的一致性。</li>
      <li><strong>Stevanato（PFS供应商）:</strong> 必须提供尺寸和硅油润滑一致的注射器，以确保柱塞运动平稳和完全输送。</li>
      <li><strong>制药客户A:</strong> 必须确保灌装过程准确和精密。灌装体积误差直接影响输送剂量。就可接受的灌装体积范围进行密切合作至关重要。</li>
    </ul>
  </li>
</ul>

<hr>

<h2>2. 激活力和用户操作</h2>

<h3>2.1. 目的</h3>

<p>确保自动注射器易于使用，并且可以由目标患者群体（包括手部力量有限的个体）激活。</p>

<h3>2.2. 参考标准</h3>

<ul>
  <li><strong>ISO 11608-1:</strong> 医疗用针式注射系统 - 要求和测试方法 - 第1部分：针式注射系统。</li>
  <li><strong>FDA指南:</strong> 组合产品设计和开发中的人因研究和相关临床研究考虑。</li>
</ul>

<h3>2.3. 设备</h3>

<ul>
  <li>带合适夹具的测力计。</li>
  <li>模拟注射垫。</li>
  <li>视频录制设备。</li>
</ul>

<h3>2.4. 样本量和方法</h3>

<ul>
  <li><strong>激活力:</strong> 每批30个设备。</li>
  <li><strong>人因研究:</strong> 每个用户组至少15名参与者，代表目标人群。</li>
</ul>

<h3>2.5. 程序</h3>

<ol>
  <li><strong>激活力:</strong>
    <ol>
      <li>将设备安装在测力计夹具中。</li>
      <li>测量移除安全帽所需的力。</li>
      <li>测量在注射垫上激活设备所需的峰值力。</li>
    </ol>
  </li>
  <li><strong>用户操作:</strong>
    <ol>
      <li>向参与者提供设备和使用说明。</li>
      <li>观察他们进行模拟注射。</li>
      <li>记录任何使用错误、困难或侥幸成功。</li>
      <li>进行用后访谈以收集反馈。</li>
    </ol>
  </li>
</ol>

<h3>2.6. 验收标准</h3>

<ul>
  <li><strong>激活力:</strong> 移除安全帽和激活设备的力必须在规定范围内（例如，移除安全帽2-5牛顿，激活15-30牛顿）。</li>
  <li><strong>用户操作:</strong> 研究必须证明用户能够安全有效地操作设备，成功率很高（例如，>95%）。</li>
</ul>

<h3>2.7. 理由与合作</h3>

<ul>
  <li><strong>理由:</strong> 该测试对于确保患者在高度紧张的紧急情况下能够正确使用设备至关重要。</li>
  <li><strong>合作:</strong>
    <ul>
      <li><strong>Summed Medtech:</strong> 设备的设计，包括机身的人体工程学和激活机制，至关重要。</li>
      <li><strong>Stevanato:</strong> 注射器的特性，如柱塞的 breakaway and gliding forces，会影响整体激活力。</li>
    </ul>
  </li>
</ul>

<hr>

<h2>3. 注射时间和针头暴露</h2>

<h3>3.1. 目的</h3>

<p>验证注射在适当的时间范围内完成，并且针头暴露的时间正确，以确保适当的药物输送。</p>

<h3>3.2. 参考标准</h3>

<ul>
  <li><strong>ISO 11608-1:</strong> 医疗用针式注射系统 - 要求和测试方法 - 第1部分：针式注射系统。</li>
</ul>

<h3>3.3. 设备</h3>

<ul>
  <li>高速摄像机（例如，>1000帧/秒）。</li>
  <li>密度与人体组织相似的泡沫块。</li>
  <li>用于分析视频片段的测量软件。</li>
</ul>

<h3>3.4. 样本量和方法</h3>

<ul>
  <li>每批30个设备。</li>
</ul>

<h3>3.5. 程序</h3>

<ol>
  <li>设置高速摄像机以记录设备在泡沫块上的激活过程。</li>
  <li>激活设备。</li>
  <li>分析视频以确定：
    <ul>
      <li>从针头开始移动到药物输送结束的时间。</li>
      <li>针头穿透泡沫块的最大深度。</li>
      <li>针头在设备外壳外暴露的总时间。</li>
    </ul>
  </li>
</ol>

<h3>3.6. 验收标准</h3>

<ul>
  <li><strong>注射时间:</strong> 在规定范围内（例如，3-10秒）。</li>
  <li><strong>针头穿透深度:</strong> 在肌肉注射的规定范围内（例如，15-25毫米）。</li>
  <li><strong>针头暴露:</strong> 注射完成后，针头应立即被屏蔽。</li>
</ul>

<h3>3.7. 理由与合作</h3>

<ul>
  <li><strong>理由:</strong> 正确的注射时间和深度对于药物的药代动力学特性至关重要。针头安全是首要的安全问题。</li>
  <li><strong>合作:</strong>
    <ul>
      <li><strong>Summed Medtech:</strong> 弹簧力和机械设计决定了注射速度和针头动态。</li>
      <li><strong>Stevanato:</strong> 针头长度和质量对于实现正确的穿透深度至关重要。</li>
    </ul>
  </li>
</ul>

<hr>

<h2>4. 设备耐久性和坚固性</h2>

<h3>4.1. 目的</h3>

<p>确保自动注射器能够承受运输和操作的物理压力，而不会影响其功能或安全性。</p>

<h3>4.2. 参考标准</h3>

<ul>
  <li><strong>ASTM D4169:</strong> 运输容器和系统性能测试的标准实践。</li>
  <li><strong>ISO 11608-1:</strong> 医疗用针式注射系统 - 要求和测试方法 - 第1部分：针式注射系统。</li>
</ul>

<h3>4.3. 设备</h3>

<ul>
  <li>跌落测试设备。</li>
  <li>振动台。</li>
  <li>环境箱（用于温湿度控制）。</li>
</ul>

<h3>4.4. 样本量和方法</h3>

<ul>
  <li>一批设备将经受每种压力条件。每个测试应使用一组单独的设备。</li>
</ul>

<h3>4.5. 程序</h3>

<ol>
  <li>根据ASTM D4169定义的协议，对设备进行一系列测试，包括：
    <ul>
      <li><strong>跌落测试:</strong> 从规定高度（例如，1米）以不同方向将设备跌落到坚硬表面上。</li>
      <li><strong>振动测试:</strong> 模拟运输过程中可能发生的振动。</li>
      <li><strong>环境测试:</strong> 将设备暴露于高低温和湿度的循环中。</li>
    </ul>
  </li>
  <li>每次压力测试后，目视检查设备是否有任何损坏。</li>
  <li>对受压设备进行所有其他功能测试（剂量准确度，激活力等）。</li>
</ol>

<h3>4.6. 验收标准</h3>

<ul>
  <li>压力测试期间不应发生严重故障（例如，裂缝、激活）。</li>
  <li>受压设备在功能测试中的性能不应与未受压的对照设备有显著差异。</li>
</ul>

<h3>4.7. 理由与合作</h3>

<ul>
  <li><strong>理由:</strong> 患者随身携带这些设备，因此它们必须足够坚固，以便在需要时可靠地发挥作用。</li>
  <li><strong>合作:</strong>
    <ul>
      <li><strong>Summed Medtech:</strong> 负责设备外壳和组件的材料选择和结构设计。</li>
      <li><strong>Stevanato:</strong> 玻璃注射器必须足够坚固，能够承受压力而不会破裂或开裂。</li>
    </ul>
  </li>
</ul>

<hr>

<h2>5. 容器封闭完整性（CCI）</h2>

<h3>5.1. 目的</h3>

<p>通过确认容器封闭系统（注射器及其组件）防止微生物侵入，确保药品的无菌性。</p>

<h3>5.2. 参考标准</h3>

<ul>
  <li><strong>USP &lt;1207&gt;:</strong> 包装完整性评估 - 无菌产品。</li>
  <li><strong>ISO 11608-3:</strong> 医疗用针式注射系统 - 要求和测试方法 - 第3部分：成品容器。</li>
</ul>

<h3>5.3. 设备</h3>

<ul>
  <li>氦气质谱检漏仪或带真空室的染料浴。</li>
</ul>

<h3>5.4. 样本量和方法</h3>

<ul>
  <li>每批中具有统计学意义的设备数量，在产品保质期开始和结束时进行测试。</li>
</ul>

<h3>5.5. 程序（氦气泄漏法）</h3>

<ol>
  <li>将设备放入充满氦气的压力室中一段时间。</li>
  <li>取出设备，将其放入连接到质谱仪的真空室中。</li>
  <li>测量从设备泄漏出的氦气速率。</li>
</ol>

<h3>5.6. 验收标准</h3>

<ul>
  <li>泄漏率必须低于与防止微生物侵入相关的最大允许限值（例如，&lt;10^-6 std-cc/sec）。</li>
</ul>

<h3>5.7. 理由与合作</h3>

<ul>
  <li><strong>理由:</strong> CCI的破坏可能导致无菌药品的污染，对患者安全构成严重风险。</li>
  <li><strong>合作:</strong>
    <ul>
      <li><strong>Summed Medtech:</strong> 自动注射器的设计不得损害PFS的完整性。组装过程至关重要。</li>
      <li><strong>Stevanato:</strong> 必须提供具有经过验证的CCI的高质量PFS。柱塞和顶帽材料的选择至关重要。</li>
      <li><strong>制药客户A:</strong> 灌装和完成过程不得损坏注射器或损害其完整性。</li>
    </ul>
  </li>
</ul>

</div>

<script>
function toggleLang(lang) {
  var en = document.getElementById('en');
  var zh = document.getElementById('zh');
  if (lang === 'en') {
    en.classList.add('active');
    zh.classList.remove('active');
  } else {
    en.classList.remove('active');
    zh.classList.add('active');
  }
}
</script>

</body>
</html>
